Triple negative breast cancer (TNBC), the most difficult type of breast carcinoma to treat, accounting for 10 to 20% of all invasive breast cancers [3], is negative for the HER2 amplification, and both progesterone receptor (PR) and estrogen receptor (ER) expression [4]. This evidence concerns the gene ESR1 and invasive breast carcinoma.